Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate

: Plöger, G.F.; Quizon, P.M.; Abrahamsson, B.; Cristofoletti, R.; Groot, D.W.; Parr, A.; Langguth, P.; Polli, J.E.; Shah, V.P.; Tajiri, T.; Mehta, M.U.; Dressman, J.


Journal of pharmaceutical sciences 109 (2020), Nr.6, S.1846-1862
ISSN: 0022-3549
ISSN: 1520-6017
Fraunhofer IME ()

Literature data and results of experimental studies relevant to the decision to allow waiver of bioequivalence studies in humans for the approval of immediate release solid oral dosage forms containing cephalexin monohydrate are presented. Solubility studies were performed in accordance with the current biowaiver guidelines of the Food and Drug Administration, World Health Organization and European Medicines Agency, taking the degradation at some pH values into consideration. Together with solubility and permeability data for cephalexin monohydrate from the literature, it was demonstrated to be a Biopharmaceutics Classification System Class 1 drug. The pharmacokinetic behavior, results of bioequivalence studies published in the literature, as well as the therapeutic uses, potential toxicity and potential excipient effects on bioavailability were also assessed. Cephalexin has a wide therapeutic index and no bioequivalence problems have been reported. Dissolution studies were run under Biopharmaceutics Classification System–biowaiver conditions for the pure drug and 2 generic formulations available on the German market. Considering all relevant aspects, it was concluded that a biowaiver-based approval for products containing cephalexin monohydrate as the single active pharmaceutical ingredient is scientifically justified, provided that well-established excipients are used in usual amounts and that both test and reference dosage forms meet the guideline criteria of either “rapidly dissolving” or “very rapidly dissolving.”